Reviewing MDxHealth (OTCMKTS:MXDHF) and SES (OTCMKTS:SGBAF)

MDxHealth (OTCMKTS:MXDHF) and SES (OTCMKTS:SGBAF) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings and profitability.

Analyst Ratings

This is a breakdown of recent ratings for MDxHealth and SES, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MDxHealth	0	0	0	0	0.00
SES	0	0	0	1	4.00

Given MDxHealth’s higher probable upside, research analysts clearly believe MDxHealth is more favorable than SES.

Earnings and Valuation

This table compares MDxHealth and SES”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MDxHealth	$37.05 million	0.00	-$44.04 million	N/A	N/A
SES	$2.20 billion	0.77	-$974.59 million	($4.18)	-0.73

MDxHealth has higher earnings, but lower revenue than SES.

Volatility & Risk

MDxHealth has a beta of 1.46, suggesting that its stock price is 46% more volatile than the S&P 500. Comparatively, SES has a beta of 1.26, suggesting that its stock price is 26% more volatile than the S&P 500.

Profitability

This table compares MDxHealth and SES’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MDxHealth	N/A	N/A	N/A
SES	-83.41%	6.16%	2.35%

Summary

SES beats MDxHealth on 5 of the 9 factors compared between the two stocks.

About MDxHealth

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use of invasive procedures that are prone to complications. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.

About SES

SES S.A. provides satellite-based data transmission capacity and ancillary services worldwide. The company offers content connectivity solutions, including network spanning satellite and ground infrastructure to create, deliver, and manage video and data solutions. It also provides data connectivity services through its fleet of geostationary earth orbit and medium earth orbit satellites to the aviation, cloud, cruise, energy, government, maritime, and telco and mobile network operator industries. In addition, the company offers video services, which includes end-to-end managed services to audience; and provides multi-screen and multi-device viewing experiences on linear channels, video-on-demand, streaming platforms, and social media sites for broadcasters, platform operators, and sports organizations. Further, it provides linear video aggregation and distribution, such as direct-to-home, direct-to-cable, and internet protocol TV households; channel management solutions comprising playout; and live feeds and redundancy features. The company was formerly known as SES Global SA and changed its name to SES S.A. in December 2006. SES S.A. was founded in 1985 and is headquartered in Betzdorf, Luxembourg.